Phase 3 Recruiting NIH
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04267848
Sites in Ohio: - Cleveland Clinic Akron General — Akron, Ohio
- Aultman Alliance Community Hospital — Alliance, Ohio
- Indu and Raj Soin Medical Center — Beavercreek, Ohio
- Strecker Cancer Center-Belpre — Belpre, Ohio
- Saint Elizabeth Boardman Hospital — Boardman, Ohio
Phase 3 Recruiting NIH
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04181060
Sites in Ohio: - UH Seidman Cancer Center at UH Avon Health Center — Avon, Ohio
- UHHS-Chagrin Highlands Medical Center — Beachwood, Ohio
- Indu and Raj Soin Medical Center — Beavercreek, Ohio
- Strecker Cancer Center-Belpre — Belpre, Ohio
- Saint Elizabeth Boardman Hospital — Boardman, Ohio
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by immunotherapy with durvalumab or target…
Sponsor: NRG Oncology
NCT ID: NCT05624996
Sites in Ohio: - Cleveland Clinic Akron General — Akron, Ohio
- UH Seidman Cancer Center at UH Avon Health Center — Avon, Ohio
- UHHS-Chagrin Highlands Medical Center — Beachwood, Ohio
- Cleveland Clinic Mercy Hospital — Canton, Ohio
- Aultman Health Foundation — Canton, Ohio
Phase 3 Recruiting Industry
This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-sm…
Sponsor: Pfizer
NCT ID: NCT07222566
Sites in Ohio: - Aultman Hospital — Canton, Ohio
- Aultman Medical Group Hematology and Oncology — Canton, Ohio
- Oncology Hematology Care Clinical Trials — Cincinnati, Ohio
- Oncology Hematology Care Clinical Trials — Cincinnati, Ohio
- Oncology Hematology Care Clinical Trials — Cincinnati, Ohio
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT06561386
Sites in Ohio: - Local Institution - 0369 — Canton, Ohio
- Local Institution - 0486 — Centerville, Ohio
- University of Cincinnati Medical Center — Cincinnati, Ohio
- Local Institution - 0199 — Cleveland, Ohio
- Local Institution - 0519 — Elyria, Ohio
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06881784
Sites in Ohio: - TriHealth Cancer & Blood Institute Research — Cincinnati, Ohio
- Taylor Cancer Research Center — Maumee, Ohio
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy of Pumitamig versus Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%.
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07361510
Sites in Ohio: - Cincinnati Veterans Affairs Medical Center — Cincinnati, Ohio
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of ZL-1310 compared to Investigator's Choice Therapy in participants with relapsed Small Cell Lung Cancer.
Sponsor: Zai Lab (Shanghai) Co., Ltd.
NCT ID: NCT07218146
Sites in Ohio: - Cleveland Clinic - Akron General Medical Center — Akron, Ohio
- University Hospitals Cleveland Medical Center — Cleveland, Ohio
- Cleveland Clinic - Fairview Hospital Molly Pavilion — Cleveland, Ohio
- Cleveland Clinic — Cleveland, Ohio
- Cleveland Clinic - Hillcrest Hospital Cancer Center — Mayfield Heights, Ohio
Phase 3 Recruiting Industry
This is a Phase III, multisite, randomized, double-blinded study to investigate pumitamig (BNT327) combined with chemotherapy (etoposide/carboplatin) compared to atezolizumab combined with chemotherapy (etoposide/carboplatin) for the treat…
Sponsor: BioNTech SE
NCT ID: NCT06712355
Sites in Ohio: - Cleveland Clinic - Akron General Hematology & Oncology — Akron, Ohio
- Cleveland Clinic Mercy Hospital Cancer Center — Canton, Ohio
- The Christ Hospital Cancer Center — Cincinnati, Ohio
- University Hospitals Cleveland Medical Center — Cleveland, Ohio
- The Cleveland Clinic Cancer Center at Fairview Hospital, Moll Pavilion — Cleveland, Ohio
Phase 3 Recruiting Industry
The primary objectives are to compare progression-free survival (PFS) and overall survival (OS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants who receive pembrolizumab with platinum doublet ch…
Sponsor: Amgen
NCT ID: NCT05920356
Sites in Ohio: - Dayton Physician's Network — Dayton, Ohio
Phase 3 Recruiting Industry
Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epidermal growth factor receptor 2 (HER2) mutations. Advanced NSCLC means lung cancer …
Sponsor: Bayer
NCT ID: NCT06452277
Sites in Ohio: - UC Medical Center - Oncology — Cincinnati, Ohio
- Taylor Cancer Research Center — Maumee, Ohio
Phase 3 Recruiting Industry
Global, Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of firmonertinib at a dose level of 240 mg QD compared to investigator's choice of osimertinib (80 mg QD) or afatinib (40 mg QD) in participants …
Sponsor: ArriVent BioPharma, Inc.
NCT ID: NCT07185997
Sites in Ohio: - Ohio State University Hospitals — Columbus, Ohio
Phase 3 Recruiting Industry
The Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab with Carboplatin plus Etoposide as Fir…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT06646276
Sites in Ohio: - Oncology Hematology Care — Cincinnati, Ohio
Phase 3 Recruiting Industry
The goal of this clinical study is to learn more about the study drug sacituzumab govitecan (SG; Trodelvy®; GS-0132; IMMU 132), versus standard of care (SOC) in participants with previously treated extensive stage small cell lung cancer (E…
Sponsor: Gilead Sciences
NCT ID: NCT06801834
Sites in Ohio: - University Hospitals Seidman Cancer Center — Sandusky, Ohio
- Taylor Cancer Research Foundation — Toledo, Ohio
Phase 3 Recruiting Industry
In this study researchers are testing Risvutatug rezetecan also known as (Ris-Rez) a new medicine that targets specific proteins (B7-H3) on cancer cells, thereby reducing the cancer's ability to grow and spread. This study specifically aim…
Sponsor: GlaxoSmithKline
NCT ID: NCT07099898
Sites in Ohio: - GSK Investigational Site — Canton, Ohio
Phase 2, Phase 3 Recruiting Industry
Arm 1 ( Phase 2/3 Run in ): PRV111: Topical Locoregional Delivery Placed Over the Tumor Region Primary Endpoint: Overall Response Rate (ORR) Primary Objective: Demonstrate the safety and efficacy of PRV111 in patients with Carcinoma in Sit…
Sponsor: Privo Technologies
NCT ID: NCT05893888
Sites in Ohio: - The Cleveland Clinic Foundation — Cleveland, Ohio
Phase 2 Recruiting Academic/Other
This phase II trial compares the effect of intensity-modulated post-operative radiation therapy (I²-PORT) followed by standard of care therapy (chemotherapy or immunotherapy) to standard of care therapy alone in treating patients with non-…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07293247
Sites in Ohio: - Ohio State University Comprehensive Cancer Center — Columbus, Ohio
Phase 1, Phase 2 Recruiting NIH
This phase I/II trial tests the safety, side effects, and best dose of iadademstat when given together with atezolizumab or durvalumab, and studies the effect of the combination in treating patients with small cell lung cancer that has spr…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06287775
Sites in Ohio: - University of Cincinnati Cancer Center-UC Medical Center — Cincinnati, Ohio
- Case Western Reserve University — Cleveland, Ohio
- Ohio State University Comprehensive Cancer Center — Columbus, Ohio
- University of Cincinnati Cancer Center-West Chester — West Chester, Ohio
Phase 2 Recruiting Network
This phase II Expanded Lung-MAP treatment trial compares how well sacituzumab govitecan alone, ivonescimab alone, or sacituzumab govitecan in combination with ivonescimab works in treating patients with non-small cell lung cancer (NSCLC) t…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT07393555
Sites in Ohio: - ProMedica Flower Hospital — Sylvania, Ohio
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combinatio…
Sponsor: Inhibrx Biosciences, Inc
NCT ID: NCT04198766
Sites in Ohio: - Cleveland Clinic — Cleveland, Ohio
Phase 2 Recruiting Industry
This trial will evaluate the efficacy and safety of various therapies in participants with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated NSCLC tumors that meet protocol-specified biomarker criteria.
Sponsor: Genentech, Inc.
NCT ID: NCT04302025
Sites in Ohio: - University Hospitals Cleveland Medical Center — Cleveland, Ohio
- Ohio State University — Columbus, Ohio
Phase 1, Phase 2 Recruiting Industry
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) o…
Sponsor: Genmab
NCT ID: NCT05579366
Sites in Ohio: - Ohio State University Comprehensive Cancer Center (OSUCCC)- The James Cancer Hospital and Solove Research Institute — Columbus, Ohio
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Sponsor: DualityBio Inc.
NCT ID: NCT05150691
Sites in Ohio: - Gabrail Cancer Center — Canton, Ohio
Phase 1, Phase 2 Recruiting Industry
This is a phase 1/2, multicenter, open-label study. The phase 1 portion is a dose escalation and expansion study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors. The phase 2 portion is a…
Sponsor: Synthekine
NCT ID: NCT05098132
Sites in Ohio: - University Hospitals Cleveland — Cleveland, Ohio
- The James Cancer Hospital and Solove Research Institute — Columbus, Ohio
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Ohio: - The Cleveland Clinic Taussig Cancer Center — Cleveland, Ohio